Gedeon Richter ($RICHTER) – A Cash-Generating Specialty Pharma Trading at a Discount?

I’ve been looking at Gedeon Richter ($RICHTER), a Hungarian pharma company that seems misclassified as a generic manufacturer. A meaningful part of its profitability comes from cariprazine royalties (marketed in the U.S. by AbbVie as Vraylar), which are high-margin and capital-light. That royalty stream scales without heavy reinvestment and adds a specialty pharma profile on top of its base business. The company also has a strong position in women’s health across Central & Eastern Europe. Financially, it has a net cash balance sheet, consistent free cash flow, and pays a dividend. This isn’t a speculative biotech story — it’s already profitable and self-funding. Valuation still looks closer to generic peers than Western European specialty pharma, despite better margins in parts of the business. If the market continues to treat it as a generic name, upside is limited. If it’s re-rated as a hybrid specialty/royalty model, there’s room for multiple expansion. Risks are royalty concentration, FX exposure, and regional sentiment, but at current pricing it looks like a reasonable quality-at-a-fair-price idea rather than a deep value trap. Curious if anyone here has dug into long-term cariprazine sustainability.